ReVision Therapeutics, Inc.

5 articles about ReVision Therapeutics, Inc.

• Aequus and reVision to Collaborate on Stargardt Disease Program

  8/17/2021

  Aequus Pharmaceuticals Inc. and reVision Therapeutics, Inc. announce a collaboration on the development of a therapy for Stargardt disease.

• reVision Therapeutics Announces US FDA Grant of Rare Pediatric Disease and Orphan-Drug Designation for REV-0100 for the Treatment of Stargardt Disease

  10/28/2020

  reVision Therapeutics, Inc., a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare diseases, today announced that the US Food and Drug Administration has granted the Company's request to designate REV-0100 as an Orphan-Drug and a Rare Pe

• reVision Therapeutics, Inc. Announces License with Cornell to Develop Treatment for Stargardt Disease

  9/1/2020

  reVision Therapeutics, Inc. ("reVision" or the "Company"), today announced that it has signed an exclusive license agreement with Cornell University ("Cornell") for the development and commercialization of Cornell's proprietary technology for the treatment of Stargardt disease, a genetic disorder that affects central vision.

• Phase 2b Data Suggest ReVision Therapeutics, Inc.'s Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients

  10/18/2010

• ReVision Therapeutics, Inc.'s Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial

  9/1/2010